News Related to Protagonist Therapeutics

Related coverage linked through entity extraction aliases.

Protagonist Reports 2025 Results, Advances Two NDAs and Expands Pipeline

Mar 05, 2026

Protagonist Therapeutics reported fourth quarter and full year 2025 financial results, with two NDAs submitted and multiple Phase 3 trials advancing. The company holds $646 million in cash and expects regulatory decisions in 2026.

FDA Accepts Rusfertide NDA and Grants Priority Review for Polycythemia Vera Treatment

Mar 02, 2026

The FDA has accepted the New Drug Application for rusfertide, a first-in-class hepcidin mimetic peptide for polycythemia vera, and granted Priority Review with a PDUFA goal date in the third quarter of 2026.